Form 4: Crinetics Pharmaceuticals Executive Reports Stock Transactio
Insider Transaction (Form 4)
Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on September 1, 2026.
Summary
- Disposition to the issuer: disposed of 58,286 Common Stock at $85.00 ($4,954,310) on September 1, 2026; holds 79,650 after (Direct).
- Disposition to the issuer: disposed of 79,650 Common Stock at $85.00 ($6,770,250) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 90,514 Stock Option (Right to Buy) at $83.09 ($7,520,808) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 74,540 Stock Option (Right to Buy) at $75.72 ($5,644,169) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 56,250 Stock Option (Right to Buy) at $59.81 ($3,364,312) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 60,000 Stock Option (Right to Buy) at $62.39 ($3,743,400) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 85,000 Stock Option (Right to Buy) at $69.71 ($5,925,350) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 15,000 Stock Option (Right to Buy) at $61.81 ($927,150) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 77,000 Stock Option (Right to Buy) at $64.98 ($5,003,460) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 110,000 Stock Option (Right to Buy) at $65.36 ($7,189,600) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 87,000 Stock Option (Right to Buy) at $41.49 ($3,609,630) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 65,000 Stock Option (Right to Buy) at $48.14 ($3,129,100) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 47,000 Stock Option (Right to Buy) at $41.21 ($1,936,870) on September 1, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Stephen F. Betz — Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Disposition to the issuer | Common Stock | 58,286 | $85 | $5.0M | 79,650 |
| 2026-09-01 | Disposition to the issuer | Common Stock | 79,650 | $85 | $6.8M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 90,514 | $83 | $7.5M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 74,540 | $76 | $5.6M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 56,250 | $60 | $3.4M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 60,000 | $62 | $3.7M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 85,000 | $70 | $5.9M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 15,000 | $62 | $927.1K | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 77,000 | $65 | $5.0M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 110,000 | $65 | $7.2M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 87,000 | $41 | $3.6M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 65,000 | $48 | $3.1M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 47,000 | $41 | $1.9M | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Disposition to the issuer (58,286 shares) |
| 2026-09-01 | Disposition to the issuer (79,650 shares) |
| 2026-09-01 | Disposition to the issuer (90,514 shares) |
| 2026-09-01 | Disposition to the issuer (74,540 shares) |
| 2026-09-01 | Disposition to the issuer (56,250 shares) |
| 2026-09-01 | Disposition to the issuer (60,000 shares) |
| 2026-09-01 | Disposition to the issuer (85,000 shares) |
| 2026-09-01 | Disposition to the issuer (15,000 shares) |
| 2026-09-01 | Disposition to the issuer (77,000 shares) |
| 2026-09-01 | Disposition to the issuer (110,000 shares) |
| 2026-09-01 | Disposition to the issuer (87,000 shares) |
| 2026-09-01 | Disposition to the issuer (65,000 shares) |
| 2026-09-01 | Disposition to the issuer (47,000 shares) |
Keywords
insider transaction, Form 4, CRNX, Crinetics Pharmaceuticals, Inc., neutral, Stephen F. Betz
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.